Spironolactone in Covid-19 Induced ARDS

• Status: Completed
• Trial end date: 2020-07-05
• Target enrollment: 0
• Participant gender: All

Summary

This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Istanbul University-Cerrahpasa
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• Hemodynamically stable

• Hypoxemia, i.e. p/f <150

• Admitted to ICU within 48 hours

• Not moribund has a life expectancy greater than 24 hours

Exclusion Criteria:

• Age criteria

• Pregnancy

• Unwillingness to participate